Abstract: A wide variety of environmental cues, including inflammatory cytokines, ligands for pattern recognition receptors and endogenous danger signals, activate the inducible transcription factor nuclear factor-κ B (NF-κ B), which is a central regulator of inflammatory and immune responses. Excessive activation of NF-κ B results in the development of severe diseases, such as chronic inflammatory disorders, autoimmune diseases and cancer. Therefore, the transcriptional activity of NF-κ B is tightly regulated at multiple steps. One mechanism is mediated by the inhibitor of κ B (I κ B), a well-defined regulator of NF-κ B that resides in the cytoplasm and prevents NF-κ B from nuclear entry by sequestration. Recently, several atypical I κ Bs that reside in the nucleus were identified: Bcl-3, I κ B ζ , I κ BNS and I κ B η . In contrast to conventional I κ Bs, these atypical I κ Bs positively and negatively modulate NF-κ B-mediated transcription. The function of atypical I κ Bs is independent of the prevention of NF-κ B nuclear entry. Therefore, atypical I κ Bs are considered distinct from conventional I κ Bs and have been termed ' nuclear I κ Bs. ' In addition to these members, our recent study indicated that I κ BL, originally reported as a susceptibility gene for rheumatoid arthritis, also serves as a nuclear I κ B. Biological and genetic studies strongly suggest that nuclear I κ Bs play important roles in the pathogenesis of inflammatory and autoimmune diseases via the regulation of both innate and adaptive immunity. In this review, we discuss the recent advances in our understanding of nuclear I κ Bs in the context of NF-κ B-mediated transcriptional regulation and inflammatory responses.
Introduction
Nuclear factor-κ B (NF-κ B) plays important roles in various biological processes, such as development, immunity, inflammation and cancer. NF-κ B activity is attributed to homodimers or heterodimers of the Rel transcription factor family: RelA (p65), RelB, c-Rel, p50 (p105, NF-κ B1) and p52 (p100, NF-κ B2) (1) . Under homeostatic conditions, these dimers are sequestered in the cytoplasm as inactive complexes in association with inhibitors of κ B (I κ B) proteins. The I κ B family of proteins, in which each protein contains multiple ankyrin repeat domains (ANKs), includes I κ B α , I κ B β , I κ B ε and I κ B δ ( Figure 1 ) (2) . Environmental stimuli elicit two distinct NF-κ B pathways (3) . In the canonical pathway, inflammatory cytokines and ligands for Tolllike receptors (TLRs), including lipopolysaccharide (LPS), induce phosphorylation and subsequent degradation of I κ B proteins, such as I κ B α , resulting in the release of RelA-or c-Rel-containing dimers, which were sequestered as an inactive complex. The released dimers move from the cytoplasm into the nucleus and activate target genes. The second NF-κ B pathway is activated by a non-canonical (alternative) mechanism. The engagement of certain tumor necrosis factor superfamily receptors proteolytically induces processing of the RelB/p100 dimer into the RelB/p52 dimer, which then translocates into the nucleus and activates target genes. Both the canonical and noncanonical NF-κ B pathways are largely involved in inflammation and lymphoid organogenesis, respectively, and are regulated by each other (4) .
Several coordinately regulated genes that are activated by NF-κ B upon inflammatory stimulation have been categorized into two groups (5) . One group, which includes the Tnfa (TNF α ) gene, is characterized by the rapid induction (within 1 h) of transcription and a CpGrich region in its promoter. Another group is defined by delayed induction (after a few hours), which requires de novo protein synthesis and chromatin remodeling. This group of genes includes IL-1 β , IL-6 and IL-12p40. These rapid and delayed-induction genes are classified as primary and secondary response genes, respectively (5) .
Once the inflammatory response is triggered, NF-κ B promotes the transcription of inflammatory cytokines as well as their regulatory molecules that are involved in feedforward and feedback regulation of NF-κ B activity (6) . Recently, it has been reported that some unique I κ B family proteins are induced by NF-κ B. These proteins, including Bcl-3, I κ B ζ , I κ BNS and I κ B η , contain multiple ANKs with homology to those of classical I κ Bs. In contrast to the classical I κ Bs, which are located in the cytoplasm, these proteins reside in the nucleus, are dependent on their nuclear localization signal sequence (NLS) and are designated as ' nuclear I κ B ' proteins ( Figure 1 ) (7, 8) . Whereas classical I κ Bs bind to Rel family proteins within the cytoplasm and mask the NLS of Rel proteins to prevent their nuclear entry, nuclear I κ Bs bind to Rel family proteins in the nucleus and thereby modulate the transcriptional activity of NF-κ B (2) .
Recently, we identified a novel member of the nuclear I κ B proteins, I κ BL (9) . I κ BL was originally reported as a susceptibility gene for rheumatoid arthritis (10, 11) . We found that I κ BL prevents collagen-induced arthritis (CIA) via the regulation of inflammatory cytokine production in antigenpresenting cells (12) . In contrast to other nuclear I κ Bs, I κ BL is gradually induced upon LPS treatment and inhibits inflammatory cytokine transcription. Therefore, we assume that I κ BL is distinct from the other previously reported nuclear I κ Bs in the context of inflammatory settings.
In this review, we highlight recent research on the nuclear I κ Bs in the regulation of inflammatory response and discuss their role in the pathogenesis of autoimmune and inflammatory disorders.
Bcl-3
B cell lymphoma-3 (Bcl-3) was originally identified as a putative proto-oncogene in chronic lymphocytic leukemia, and elevated expression of Bcl-3 has been detected in a wide variety of cancer types (13) . Bcl-3 contains seven ANKs with similarities to those of the Rel family members p105 and p100 and preferentially associates with p50/p52 homodimers, which suggests that Bcl-3 acts as an I κ B (14, 15) . Unlike classical I κ Bs, Bcl-3 is mainly localized in the nucleus and has a well-defined transcriptional activation domain. The oncogenic function of Bcl-3 relies, at least in part, on the transcriptional activation of cyclin D1 and MDM2, both of which are involved in cell cycle progression (16, 17) . It is known that Bcl-3 is an inhibitor of NF-κ B. NF-κ B-mediated TNF α transcription is suppressed by the recruitment of Bcl-3, which forms complexes with p50 homodimers on the TNF α gene promoter (18) . In addition, Bcl-3 prevents p50 ubiquitination and proteasomal degradation. In Bcl-3-deleted macrophages, RelA and c-Rel binding to the TNF α promoter is stable both in homeostatic and LPS-activated conditions (19) . Indeed, mice that were injected with Bcl-3-deficient bone marrow cells died of severe septic shock following repetitive intraperitoneal injections of LPS, whereas control mice that received normal bone marrow cells did not (19) . These results suggest that Bcl-3 plays key roles in the transcriptional control of TNF α throughout the inflammatory response. The physiological functions of Bcl-3 in the immune system have also been examined using Bcl-3-deficient mice. The formation of germinal centers and splenic structures is severely impaired in Bcl-3-deficient mice (20, 21) . Furthermore, Bcl-3-deficient mice fail to produce antigen-specific antibodies after infection with Streptococcus pneumonia , although total immunoglobulin levels are not altered (21) . Expression of GATA-3, a transcription factor indispensable for Th2 cell differentiation, is decreased in Bcl-3-deficient T cells. These findings suggest that Bcl-3 may play a crucial role in the induction of the Th2-type response in vivo (22) .
Elimination of self-reactive T cells in the thymus, which is known as negative selection, is important for establishing immunological tolerance to self (23) . The generation and development of medullary thymic epithelial cells (mTECs) are considered central to this process. Loss of both Bcl-3 and its partner p52 results in impaired differentiation of mTEC and expression of AIRE, a crucial factor for ectopic expression of tissue-restricted self-antigens in mTECs (24) . Therefore, mutant animals show a profound breakdown of central tolerance and die earlier due to multi-organ inflammation (24) . Bcl-3, expressed in cells of both hematopoietic and non-hematopoietic origin, is indispensable for control of the immune and inflammatory responses.
I κ B ζ
I κ B ζ (also known as MAIL and INAP) was first described in three independent investigations as an LPS-induced, nuclear-resident protein with high homology to Bcl-3 (25 -27) . I κ B ζ expression is rapidly induced by IL-1/TLR within 1 h in a MyD88-dependent manner; however, expression is not induced by TNF α signaling. The I κ B ζ promoter contains an NF-κ B-binding element, which is crucial for its expression (28) . It has been reported that I κ B ζ has 3 different isoforms: I κ B ζ (L), I κ B ζ (S) and I κ B ζ (D). I κ B ζ (D) lacks an N-terminal transactivation domain, and thus may act as a dominant negative form of I κ B ζ (29) .
I κ B ζ -deficient cells have altered expression of a set of genes, especially secondary response genes. The expression of secondary response genes, such as IL-6, IL-12p40 and GM-CSF, are severely impaired in I κ B ζ -deficient cells after exposure to LPS, although the expression of primary response genes, such as TNF α and Cxcl2, is not impaired, but in fact is slightly increased (30) . I κ B ζ forms a complex with the p50 homodimer and is recruited to the promoters of secondary response genes. I κ B ζ has been shown to be required for the trimethylation of histone 3 Lys-4 (H3K4), a histone marker for the transcriptionally active state, and the subsequent recruitment of the pre-initiation complex containing RNA polII, TATA-binding protein (TBP) and RelA (31) . However, the ATP-dependent nucleosome remodeling factor Brg1 is normally associated with promoters in the absence of I κ B ζ . Therefore, I κ B ζ acts independently of nucleosome remodeling through SWI/ SNF family proteins such as Brg1. It should be noted that the binding sites for CCAAT/enhancer binding protein (C/EBP)-β and NF-κ B are crucial for the transcriptional control of some genes by I κ B ζ (32) .
IL-17A in combination with TNF α , but neither alone, induces expression of I κ B ζ (28) . In contrast, it has been reported that I κ B ζ is regulated at the posttranscriptional and transcriptional levels (28) . IL-17A stimulation leads to the stabilization and sustained expression of I κ B ζ mRNA after exposure to LPS (28) . Therefore, it is assumed that IL-17A modulates I κ B ζ expression at the transcriptional and posttranscriptional levels. Recently, it has been shown that I κ B ζ is highly expressed in IL-17A-producing
CD4
+ T cells (Th17 cells) and is indispensable for the differentiation and function of these cells (33) . However, it is not clear whether the high level of I κ B ζ expression in Th17 cells reflects its mRNA stabilization via autocrine IL-17A stimulation or direct transcriptional activation by IL-17A.
To evaluate the physiological role of I κ B ζ , I κ B ζ -deficient mice were generated. The I κ B ζ -deficient mice grew normally after birth, but manifested atopic dermatitis-like lesions from 4 -5 weeks of age and have higher concentrations of serum IgE (34) . Elevated expression of TARC and eotaxin, both of which are known chemoattractants for Th2 cells and eosinophils, were observed in the skin of I κ B ζ -deficient mice. In contrast, myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis (EAE), a mouse model of human multiple sclerosis, is completely prevented by I κ B ζ deficiency (33) . As Th17 cells play a central role in the pathogenesis of EAE (35) , it is plausible that I κ B ζ is, at least in part, involved in the other Th17-mediated immunopathologies, such as rheumatoid arthritis and psoriasis.
I κ BNS
I κ BNS was originally identified as a protein that was expressed in T cells undergoing negative selection in the thymus (36) . However, mice deficient for Nfkbid , which encodes I κ BNS, exhibit no significant differences in the development of T cells, both in the thymus and the periphery, except for decreased IL-2 production and reduced proliferative capacity (37) . The lower proliferative capacity of I κ BNS-deficient T cells is rescued by exogenously supplied IL-2, which indicates that I κ BNS modulates expansion of T cells through the regulation of IL-2 production (38) . In contrast, developmental defects are observed in B1, germinal centers and marginal zone B cells of I κ BNSdeficient mice (39) . Furthermore, plasma cell differentiation is also impaired. The total amounts of IgM and IgG3 in the serum and T cell-dependent/-independent antigenspecific immunoglobulins are reduced in I κ BNS-deficient mice. Delayed, but equivalent production of antigen-specific IgG1 was observed in I κ BNS-deficient mice. However, normal IgG1 production is restored in the presence of WT T cells, which suggests that I κ BNS expressed in T cells is required for optimal antigen-specific IgG1 production (39) .
It has been shown that I κ BNS plays important roles in both innate and acquired immunity. TLR ligands strongly and rapidly induce I κ BNS mRNA expression in macrophages (38) . Increased production of some secondary response genes, but no primary response genes, is observed in I κ BNS-deficient macrophages. I κ BNS binds to the p50 subunit of NF-κ B and to the stabilized p50 homodimer, which is a transcriptionally inactive dimer, on the IL-6 promoter (40) . Prolonged binding of the RelA/ p50 dimer to the promoter is observed in I κ BNS-deficient macrophages (38) . Thus, I κ BNS is a transcriptional repressor of delayed-expressing cytokines.
It was reported that the anti-inflammatory cytokine IL-10, as well as LPS, induces I κ BNS and that I κ BNS is crucial for the prevention of LPS-induced endotoxin shock. I κ BNS is constitutively expressed in colonic macrophages, which are constantly exposed to microbiota, which suggests that I κ BNS plays a role in regulating the mucosal immune system. Indeed, I κ BNS-deficient mice exhibit higher sensitivity to DSS-induced colitis and increased IFN γ production in CD4
+ T cells (38) . Furthermore, I κ BNS deficiency leads to increased production of secondary response genes such as IL-12p40, which indicates that the loss of I κ BNS promotes a Th1-skewed environment in the context of inflammation.
I κ B η
Ankrd42 encodes an 8 ANK-containing protein with significant homology to I κ B β . The Ankrd42 gene product resides in the nucleus and binds to the p50 subunit of NF-κ B. A small interfering RNA (siRNA)-mediated knockdown of Ankrd42 exhibited reduced expression of both primary and secondary response genes, such as TNF α and IL-6, respectively. Thus, the Ankrd42 gene product is a nuclear I κ B family member and is designated I κ B η (8) . I κ B η is ubiquitously expressed in a wide variety of tissues, including immune cells. Although nuclear I κ B is inflammation inducible, I κ B η is only marginally induced by TLR agonists and is constitutively expressed at the basal level. It has been suggested that constitutive expression of I κ B η enables it to control both primary and secondary response genes. As the silencing of I κ B η in macrophages by siRNA does not affect the induction of I κ B ζ expression, I κ B η may act independently of I κ B ζ in NF-κ B-mediated gene activation.
I κ BL
NFKBIL1 , which encodes the inhibitor of κ B-Like (I κ BL), is located in the MHC class III region and was originally reported as a susceptibility gene for rheumatoid arthritis (10, 11) . We found that forced expression of I κ BL in mice reduced the severity of CIA and collagen antibodyinduced arthritis via the regulation of antigen-presenting cell function (12) . Given that SNPs within the NFKBIL1 gene locus are also associated with chronic thromboembolic pulmonary hypertension, Takayasu ' s arteritis and type I diabetes among Japanese and ulcerative colitis, SLE and Sjogren ' s syndrome in Caucasians, I κ BL may play a role in the pathogenesis of these disorders (10, 11, 41, 42) .
In human cells, the NFKBIL1 gene generates four different isoforms by alternative splicing that are designated I κ BL-α (L), -α (S), -β (L) and -β (S). In rodents, only two isoforms, α (L) and α (S), are generated (9, 43) . Two ANKs reside in the N-terminus of the I κ BL protein and show significant homology to those of I κ Bs. Although an early study suggested that I κ BL did not modulate NF-κ B activity (44) , we have shown that I κ BL suppresses LPS-induced NF-κ Bdriven luciferase activity and reduces the expression of some inflammatory cytokines in macrophages. However, the truncation of the ANK in I κ BL resulted in a failure to inhibit NF-κ B activity. This evidence suggests that I κ BL functions as an I κ B. We and others have reported that I κ BL is localized in the nucleus in an NLS-dependent manner (9, 43 ) . An NLS-truncated form of I κ BL as well as an ANK-truncated mutant had no suppressive effect on NF-κ B-driven luciferase activity. These results strongly suggest that I κ BL is a novel nuclear I κ B (9) . Intriguingly, we found that I κ BL binds specificity to the RelB NF-κ B subunit through its ANK domain, whereas all other nuclear I κ B proteins have been shown to bind to the p50 subunit of NF-κ B (our unpublished observation). As RelB was originally identified as a Rel-related protein that had an inhibitory effect on NF-κ B-dependent gene activation, I κ BL might be involved, coordinately with RelB, in the transcriptional repression of inflammatory cytokines (45) . As seen in I κ B η , I κ BL is also expressed at the basal level, but is gradually induced after exposure to TLR ligands, such as LPS and CpG, for up to 24 h. Therefore, it is plausible that I κ BL plays a role in the later phase as well as the acute phase of the inflammatory response. In agreement with the results of our studies, it was shown that I κ BL inhibits both LPS-induced NF-κ B and IRF activation via association with Cactin, which interacts with Drosophia cactus and is a mammalian ortholog I κ B α (46) . Taken together, these results suggest that I κ BL plays a unique role in the suppression of NF-κ B activity downstream of TLR signaling.
Roles of classical I κ Bs in the nucleus
Some recent evidence clearly indicates that classical I κ Bs, such as I κ B α and I κ B β , also act in the nucleus as well as in the cytoplasm. I κ B α contains a nuclear export signal (NES) in its N-terminus and continuously shuttles Relcontaining dimers between the cytoplasm and nucleus via its NES (2) . Targeted knock-in mice that harbored a mutation in the NES were generated and showed a reduced number of mature B cells and altered formation of secondary lymphoid tissue (47) . These might be attributed to the reduction in c-Rel and p100 expression and impairment of both classical and alternative NF-κ B activation. However, this does not clearly explain why nuclear export of I κ B α is crucial for maintenance of constitutive and/or signalinduced NF-κ B activation. Like I κ B α , I κ B β is also degraded and subsequently re-synthesized upon LPS stimulation. Newly synthesized I κ B β is hypophosphorylated and can be detected in the nucleus. Two recent studies have shown that de novo synthesized and poorly phosphorylated I κ B β forms a complex with the RelA/c-Rel dimer and facilitates recruitment of the complex to the promoters of genes such as IL-1 β , IL-6 and TNF α , but not to Cxcl2 promoters (48, 49) . I κ B β -deficient macrophages show rapid loss of IL-1 β , IL-6 and TNF α mRNA and decreased production of these cytokines. Therefore, nuclear I κ B β associating with RelA/ c-Rel dimers may prolong the expression of certain genes. I κ B β -deficient mice display delayed onset and decreased severity of CIA and a reduced amount of TNF α in serum (48) . These data suggest that I κ B β plays dual roles in the inflammatory response, as a cytoplasmic inhibitor of NF-κ B and a nuclear activator of some target genes. Finally, characteristics of nuclear I κ Bs described above are summarized in Table 1 .
Spatiotemporal regulation of NF-κ B activity by nuclear I κ Bs
The transcriptional activity of inflammatory cytokine genes can be divided into three different states: poised, activated and silenced (Figure 2 ) (50) . Nuclear I κ Bs, as described above, act in distinct states. Under homeostatic conditions, NF-κ B binding elements in the promoters of inflammatory cytokine genes, such as TNF α , are occupied by the p50 homodimer. The p50 homodimer lacks transcriptional activity but recruits a corepressor complex, including NCoR and SMRT, to the inflammatory cytokine gene and keeps the loci in the ' poised ' state (5, 50) . This state is actively maintained by Bcl-3, which blocks polyubiquitination and subsequent degradation of p50. Consequently, the gene loci are held poised for transcription (Figure 2A ) (19) .
Once activated via TLR signaling, the NF-κ B dimer, which translocates into the nucleus, can initiate a series of transcriptional programs of various inflammatory cytokine genes ( Figure 2B ). First, primary response genes such as TNF α are rapidly induced without de novo protein synthesis. It was reported that RNA polymerase II constitutively binds to the proximal promoter regions of most primary response genes as well as housekeeping genes, even under homeostatic conditions. The RelA-containing dimer, which binds to the κ B element of the promoter, can induce histone H4 acetylation, P-TEFb recruitment and subsequent phosphorylation of RNA polII at Ser2 (51) . TLR-induced phosphorylation of PolII at Ser2 results in productive elongation and subsequent processing of mRNA. Concurrently, inducible transcriptional modulators, such as I κ B ζ , C/EBP δ and ATF3, are also induced by the RelA-containing dimer (6, 28, 52) .
For the induction of most secondary response genes, de novo synthesized I κ B ζ is required. I κ B ζ deficiency results in a failure to promote H3K4 trimethylation, which is a histone marker for the transcriptionally active state, and a failure to recruit RNA polII and TBP to the promoters of secondary cytokine genes such as IL-6 and IL-12p40. However, recruitment of Brg1, an ATP-dependent chromatin-remodeling factor, is not influenced by I κ B ζ deficiency. Thus, pre-initiation complex recruitment, but not (B) Inflammatory stimuli rapidly induce nuclear entry of the NF-κ B dimer and convert the gene loci to the activated state. I κ B η and I κ BL, which are expressed at basal levels, respectively promote and inhibit NF-κ B-mediated inflammatory cytokine gene expression. I κ B ζ and I κ BNS are rapidly induced by TLR agonists and modulate NF-kB activity via association with p50 homodimer. I κ B ζ facilitates transcription of secondary response genes through its transcriptional activation potency or induction of H3K4 trimethylation, a marker of active transcription, at the promoters. In contrast, I κ BNS exerts an inhibitory effect on transcription by stabilization of the p50 homodimer and blockade of RelA-containing dimer binding to the promoters. Newly synthesized and hypophosphorylated-I κ B β is involved in the sustained expression of inflammatory cytokines. (C) DNA-bound RelB can recruit the histone methyltransferase G9a and histone deacetylases (HDACs) to the promoter region resulting in the induction of facultative heterochromatin formation. I κ BL, which associates with RelB, might be involved in RelB-mediated transcriptional termination. Bcl-3, which binds to p50 homodimer on the promoter, also recruits HDAC and induces termination of transcription. Bcl-3 and I κ BNS, both of which are induced by pro-or anti-inflammatory stimuli, maintain the silenced but poised chromatin structure for transcription. The red and blue arrows indicate stimulatory and inhibitory effects on transcription, respectively. Nuclear I κ Bs are shown in red text. Ub, ubiquitin.
nucleosome remodeling, at secondary response gene loci is controlled by I κ B ζ (31) .
In contrast to I κ B ζ , I κ BNS is an inducible repressor of secondary response genes. I κ BNS deficiency leads to prolonged association of RelA on the IL-6 promoter, whereas forced expression of I κ BNS completely inhibits RelA recruitment to the promoter. Therefore, I κ BNS has the opposite effect of I κ B ζ on the transcriptional activation of secondary response genes (38, 40) . I κ B β acts as an activator and an inhibitor of inflammatory cytokine transcription. Upon LPS stimulation, I κ B β -deficient cells showed a rapid loss of mRNA after its expression reached maximum, resulting in reduced production of IL1 β and TNF α . Unlike I κ B ζ , which associates with the p50 homodimer, the hypophosphorylated form of I κ B β specifically binds to the RelA/c-Rel heterodimer and facilitates prolonged production of TNF α and IL1 β . It has been suggested that those cytokines that are largely regulated by c-Rel are the targets of I κ B β -containing complexes (48) . Therefore, I κ B β and I κ B ζ have distinct roles in the temporal regulation of inflammatory cytokine expression, even though they share some target genes. Basal expression of I κ B η is considered crucial for the regulation of a wide variety of cytokines and chemokines, including both primary and secondary response genes. Although the precise role of I κ B η in the epigenetic control of transcription is currently unknown, I κ B η can form a complex with RelA and the p50 heterodimer in the promoter region of the IL-6 gene, raising the possibility that I κ B η facilitates inflammatory cytokine expression in cooperation with RelA (8) .
The termination of inflammatory cytokine gene transcription and facultative heterochromatin formation at these loci are thought to prevent excessive inflammatory response ( Figure 2C ). RelB was originally identified as a Rel-related protein that showed an inhibitory effect on NF-κ B-dependent gene activation (45) . The RelB-mediated inhibitory effect is due to its competitive binding to RelA and/or c-Rel binding sites and induction of facultative heterochromatin formation through recruitment of histone methyltransferase, histone deacetylase and DNA methyltransferase (50, 53 -55) . We found that I κ BL bound to RelB and was required to maintain transcriptional silencing of inflammatory cytokines such as IL-1 β . Short hairpin RNA-mediated knockdown of I κ BL resulted in the breakdown of LPS-induced endotoxin tolerance (our unpublished observations). LPS-induced delayed expression of Bcl-3 is also required for the repression of TNF α (18) . Bcl-3-deficient macrophages showed sustained expression of TNF α in the later phase of inflammation. Bcl-3 is induced by LPS in a p50-dependent manner and associates with p50 itself. HDAC1 is also induced by LPS stimulation with kinetics similar to Bcl-3, and it forms a complex with Bcl-3. HDAC activity is indispensable for Bcl-3-mediated TNF α repression. Taken together, I κ BL and Bcl-3, coupled with RelB and p50, respectively, might be involved in active transcriptional silencing and prevention of excess inflammatory cytokine production.
Concluding remarks
Recent progress in the field of nuclear I κ Bs has provided important insights into the transcriptional regulation of inflammatory cytokines controlled by NF-κ B. Nuclear I κ Bs may contribute to the epigenetic modulation of gene loci for optimal activation and transcriptional silencing. However, how each nuclear I κ B coordinately regulates temporal transcription through NF-κ B is almost completely unknown. Thus, further studies using mice or cells lacking two or more nuclear I κ B proteins are needed to elucidate the transcriptional circuitry of NF-κ B target genes controlled by nuclear I κ Bs. Understanding the epigenetic control of cytokine gene loci by nuclear I κ Bs in the later phase as well as in the acute phase of inflammation may shed light on the pathogenesis of inflammatory disorders.
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